In a busy news day for Takeda, the company says it has snapped up privately held US firm Intellikine in a cash deal worth up to $310 million in upfront and milestone payments. The move gives Takeda a greater footing in oncology, with a specific focus on small molecule kinase inhibitors.
Intellikine's most advanced compound is INK128, an mTORIC1/2 inhibitor, which is expected to progress to Phase II studies in 2012. Both this compound and INK1117 - a PI3K-alpha inhibitor - will fall under the watchful eye of Millennium, Takeda's oncology arm.
US OK for Edarbyclor
Meanwhile the Japanese company has been given a green light from the US Food and Drug Administration for its blood pressure lowering drug Edarbyclor (azilsartan medoxomil/chlorthalidone) - becoming the only fixed dose therapy in the USA to combine an angiotensin II receptor blocker with the diuretic chlorthalidone in a once-daily, single dose. The company will be hoping these key characteristics will enable it to take a slice of the lucrative bp lowering market - clinical studies showed a superior benefit of Edarbyclor to the fixed dose combination of olmesartan and hydrochlorothiazide, "regardless of age, gender or age", it says.
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.